To assess whether pharmacists’ proactive outreach to patients with CKD and type 2 diabetes would be associated with increased initiation of SGLT2 inhibitor use, specifically measuring initiation rates and patient outcomes.
Key Findings:
SGLT2 inhibitors significantly reduce CKD progression and improve patient outcomes, with initiation rates increasing by X% in the intervention group.
Pharmacists can effectively identify and initiate treatment with SGLT2 inhibitors in eligible patients.
Low prescribing patterns of SGLT2 inhibitors indicate a need for proactive outreach.
Interpretation:
The study suggests that pharmacist-led interventions can enhance the initiation of SGLT2 inhibitors among patients with CKD and diabetes, addressing underutilization of these beneficial medications.
Limitations:
The pseudorandomization method may not ensure perfect balance in patient characteristics, potentially affecting the study's validity.
The study did not require informed consent, which may limit generalizability.
Conclusion:
Engaging pharmacists in the management of CKD and diabetes can improve the initiation of SGLT2 inhibitors, potentially leading to better patient outcomes and addressing current underutilization.
by Deborah L. Pestka, Daniel Murphy, Adam N. Kaplan, Brent C. Taylor, Pearl Huynh, Jessica A. Rechtzigel, Shari Kjos, Lisa Marie Ellich, Melissa Atwood, Beth A. Polsfuss, Amber R. Thomas, Joseph Y. Lee, Areef Ishani
